Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Differential effect of adjuvant taxane-based and taxane-free chemotherapy regimens on the CK-19 mRNA-positive circulating tumour cells in patients with early breast cancer.
Xenidis N, Perraki M, Apostolaki S, Agelaki S, Kalbakis K, Vardakis N, Kalykaki A, Xyrafas A, Kakolyris S, Mavroudis D, Georgoulias V. Xenidis N, et al. Among authors: xyrafas a. Br J Cancer. 2013 Feb 19;108(3):549-56. doi: 10.1038/bjc.2012.597. Epub 2013 Jan 17. Br J Cancer. 2013. PMID: 23329233 Free PMC article.
Predictive and prognostic value of LPS-stimulated cytokine secretion in metastatic non-small cell lung cancer.
Vlachostergios PJ, Gioulbasanis I, Ghosh S, Tsatsanis C, Papatsibas G, Xyrafas A, Hatzidaki E, Vasiliou C, Kamposioras K, Agelaki S, Margioris AN, Nasi D, Georgoulias V, Papandreou CN. Vlachostergios PJ, et al. Among authors: xyrafas a. Clin Transl Oncol. 2013 Nov;15(11):903-9. doi: 10.1007/s12094-013-1021-5. Epub 2013 Mar 5. Clin Transl Oncol. 2013. PMID: 23463594
Effect of front-line chemotherapy on circulating CK-19 mRNA-positive cells in patients with metastatic breast cancer.
Georgoulias V, Apostolaki S, Bozionelou V, Politaki E, Perraki M, Georgoulia N, Kalbakis K, Kotsakis A, Xyrafas A, Agelaki S, Mavroudis D. Georgoulias V, et al. Among authors: xyrafas a. Cancer Chemother Pharmacol. 2014 Dec;74(6):1217-25. doi: 10.1007/s00280-014-2598-2. Epub 2014 Oct 26. Cancer Chemother Pharmacol. 2014. PMID: 25344760 Clinical Trial.
Trastuzumab decreases the incidence of clinical relapses in patients with early breast cancer presenting chemotherapy-resistant CK-19mRNA-positive circulating tumor cells: results of a randomized phase II study.
Georgoulias V, Bozionelou V, Agelaki S, Perraki M, Apostolaki S, Kallergi G, Kalbakis K, Xyrafas A, Mavroudis D. Georgoulias V, et al. Among authors: xyrafas a. Ann Oncol. 2012 Jul;23(7):1744-50. doi: 10.1093/annonc/mds020. Epub 2012 Feb 29. Ann Oncol. 2012. PMID: 22377561 Free article. Clinical Trial.
28 results